BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31109701)

  • 21. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral immune responses to Epstein-Barr virus encoded tumor associated proteins and their putative extracellular domains in nasopharyngeal carcinoma patients and regional controls.
    Paramita DK; Fatmawati C; Juwana H; van Schaijk FG; Fachiroh J; Haryana SM; Middeldorp JM
    J Med Virol; 2011 Apr; 83(4):665-78. PubMed ID: 21328382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H; Ayadi W; Fki L; Hammami A; Daoud J; Drira MM; Frikha M; Jlidi R; Middeldorp JM
    J Med Virol; 2005 Apr; 75(4):593-602. PubMed ID: 15714486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients.
    Hadar T; Rahima M; Kahan E; Sidi J; Rakowsky E; Sarov B; Sarov I
    J Med Virol; 1986 Dec; 20(4):329-39. PubMed ID: 3025351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
    Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
    J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated blood levels of soluble tumor necrosis factor receptors in nasopharyngeal carcinoma: correlation with humoral immune response to lytic replication of Epstein-Barr virus.
    Feng P; Chan SH; Ooi EE; Soo MY; Loh KS; Wang D; Ren EC; Hu H
    Int J Oncol; 1999 Jul; 15(1):167-72. PubMed ID: 10375611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.
    Fachiroh J; Stevens SJ; Haryana SM; Middeldorp JM
    J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IgA directed against early antigen of Epstein-Barr virus is no specific marker for the diagnosis of nasopharyngeal carcinoma.
    Sigel G; Schillinger M; Henninger K; Bauer G
    J Med Virol; 1994 Jul; 43(3):222-7. PubMed ID: 7931181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of logistic regression in combination with multiple diagnostic tests for auxiliary diagnosis of nasopharyngeal carcinoma.
    Jiang SQ; Liu Q
    Ai Zheng; 2009 Feb; 28(2):177-80. PubMed ID: 19550133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.